CH0334081137 - Common Stock
CRISPR THERAPEUTICS AG
NASDAQ:CRSP (4/26/2024, 9:17:10 AM)
54.83
+1.1 (+2.05%)
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug and currently employs 458 full-time employees. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
CRISPR THERAPEUTICS AG
Baarerstrasse 14
Zug ZUG CH-6300
P: 41415613279
CEO: Samarth Kulkarni
Employees: 458
Website: https://crisprtx.com/
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
Vertex is broadening its portfolio.
ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
Crispr Therapeutics stock is within one standard deviation of a historically bullish trendline
There's no guarantee these stocks will double by 2030, but their growth prospects look great.
Here you can normally see the latest stock twits on CRSP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: